Access to new medicines in the NHS | Update Explainer by the King’s Fund

The King’s Fund has published an updated and expanded explainer, commissioned by the Association of the British Pharmaceutical Industry (ABPI), which builds upon the initial document published in 2020 and describes the processes that decide whether NHS services in England will pay for patients to receive new medicines. This encompasses:

• Initial development and testing
• National Institute for Health and Care Excellence’s (NICE) appraisal of their cost-effectiveness
• Negotiations between the NHS and pharmaceutical companies that can be required to agree prices

This explainer explored how much the NHS spends on new medicines and how policy-makers seek to shape and control this spending, as well as what uptake of new medicines looks like in practice.

Read the full explainer below.

Source: Access To New Medicines In The English NHS | The King’s Fund